Ovary, Phase I

A Phase 1 Clinical Study of NXP800 in Subjects With Advanced Cancers and Expansion in Subjects With Ovarian Cancer

Volunteers
Health Professionals

What is the purpose of this trial?

The purpose of the dose escalation phase is to evaluate the safety profile of escalating doses and dose schedules of NXP800. In the expansion phase the preliminary efficacy in subjects with ARID1a mutated ovarian clear cell and ovarian endometrioid cancers will be estimated.

Trial with
Nuvectis Pharma, Inc.
Gender
Female only

Find out more about who can participate in this trial

Contact Information

For more information about this study, including how to volunteer, contact Amy Nicoletti

Help Us Discover!

You can help our team find trials you might be eligible for by creating a volunteer profile in MyChart. To get started, create a volunteer profile, or contact helpusdiscover@yale.edu, or call 877.978.8343 for more information.

Create a volunteer profile

Principal Investigator

Alessandro Santin, MD
Professor of Obstetrics, Gynecology, and Reproductive Sciences; Clinical Research Team Leader, Gynecologic Oncology, Yale Cancer Center; Co-Chief, Section of Gynecologic Oncology

Sub-Investigators

Last Updated
09/27/2024
Study HIC
#2000035660